1. Poynard T，Ratziu V，McHutchison J，et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003；38：75-85.

2. L Fartoux，A Poujol-Robert，J Guéchot，et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C.Gut 2005；54（7）：1003-1008.

3. L Rubbia-Brandt，P Fabris，S Paganin，et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004；53（3）：406-412.

4. S Zeuzem，T Berg，B Moeller，et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009；16（2）：75-90.

5. T Asselah，L Rubbia-Brandt，P Marcellin，et al. Steatosis in chronic hepatitis C：why does it really matter？Gut 2006；55（1）：123-130.

6. Richard K Sterling，Melissa J Contos，Paula G Smith，et al. Steatohepatitis：Risk Factors and Impact on Disease Severity in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. Hepatology 2008；47（4）：1118-1127.

7. Nyingi Kemmer and Guy W Neff. Managing chronic hepatitis C in the difficult-to-treat patient. Liver Int 2007；27（10）：1297-1310.